β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells
The clinical utilization of fenbendazole (FBZ) as a potential anticancer drug has been limited due to its low water solubility, which causes its low bioavailability. The development of a drug nanoformulation that includes the solubilizing agent as a drug carrier can improve solubility and bioavailab...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
MDPI AG
2022-04-01
|
| Collection: | Pharmaceutics |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/1999-4923/14/4/884 |